• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

RB and CHASER as induction therapy for transplant-eligible mantle cell lymphoma.

作者信息

Saito Toko, Kusumoto Shigeru, Yanada Masamitsu, Kato Seiichi, Kagami Yoshitoyo, Kawaguchi Yuka, Taji Hirofumi, Hagiwara Shinya, Hosoda Waki, Yamamoto Kazuhito

机构信息

Department of Hematology and Cell Therapy, Aichi Cancer Center, Aichi, Japan.

Department of Hematology, Nagoya City University East Medical Center, Aichi, Japan.

出版信息

J Clin Exp Hematop. 2025;65(2):158-161. doi: 10.3960/jslrt.25011.

DOI:10.3960/jslrt.25011
PMID:40582840
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12351246/
Abstract
摘要

相似文献

1
RB and CHASER as induction therapy for transplant-eligible mantle cell lymphoma.RB和CHASER作为适合移植的套细胞淋巴瘤的诱导疗法。
J Clin Exp Hematop. 2025;65(2):158-161. doi: 10.3960/jslrt.25011.
2
R-High-CHOP/CHASER/LEED with autologous stem cell transplantation in newly diagnosed mantle cell lymphoma: JCOG0406 STUDY.在新诊断的套细胞淋巴瘤中采用 R-High-CHOP/CHASER/LEED 联合自体干细胞移植：JCOG0406 研究。
Cancer Sci. 2018 Sep;109(9):2830-2840. doi: 10.1111/cas.13719. Epub 2018 Jul 28.
3
Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma.利妥昔单抗/苯达莫司汀和利妥昔单抗/阿糖胞苷诱导疗法用于适合移植的套细胞淋巴瘤
Blood Adv. 2020 Mar 10;4(5):858-867. doi: 10.1182/bloodadvances.2019001355.
4
Molecular response after obinutuzumab plus high-dose cytarabine induction for transplant-eligible patients with untreated mantle cell lymphoma (LyMa-101): a phase 2 trial of the LYSA group.奥妥珠单抗联合大剂量阿糖胞苷诱导治疗适合移植的初治套细胞淋巴瘤患者（LyMa-101）后的分子反应：LYSA组的2期试验
Lancet Haematol. 2020 Nov;7(11):e798-e807. doi: 10.1016/S2352-3026(20)30291-X. Epub 2020 Sep 21.
5
Impact of Pre-transplant Induction Therapy on Outcomes of Patients Who Undergo Autologous Stem Cell Transplantation for Mantle Cell Lymphoma in First Complete Remission.移植前诱导治疗对处于首次完全缓解期的套细胞淋巴瘤患者进行自体干细胞移植结局的影响。
Hematol Oncol Stem Cell Ther. 2023 Jan 17;16(2):154-157. doi: 10.1016/j.hemonc.2021.07.005.
6
Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial.套细胞淋巴瘤患者在首次缓解后接受自体造血干细胞移植后的长期生存：一项开放标签、多中心、随机、3 期试验的事后分析。
Lancet Haematol. 2021 Sep;8(9):e648-e657. doi: 10.1016/S2352-3026(21)00195-2.
7
A comprehensive analysis of the role of stem cell transplantation in mantle cell lymphoma: real-world data from the Korean Society of Blood and Marrow Transplantation registry: Stem cell transplantation outcomes in mantle cell lymphoma.干细胞移植在套细胞淋巴瘤中的作用综合分析：来自韩国血液与骨髓移植学会登记处的真实世界数据：套细胞淋巴瘤的干细胞移植结果
Blood Res. 2025 Aug 13;60(1):44. doi: 10.1007/s44313-025-00092-4.
8
Bendamustine/Rituximab Plus Cytarabine/Rituximab, With or Without Acalabrutinib, for the Initial Treatment of Transplant-Eligible Mantle Cell Lymphoma Patients: Pooled Data From Two Pilot Studies.苯达莫司汀/利妥昔单抗联合阿糖胞苷/利妥昔单抗，加或不加阿卡替尼，用于适合移植的套细胞淋巴瘤患者的初始治疗：两项初步研究的汇总数据。
Clin Lymphoma Myeloma Leuk. 2023 Jul;23(7):552-560. doi: 10.1016/j.clml.2023.04.003. Epub 2023 Apr 24.
9
A phase 2 study of Rituximab-Bendamustine and Rituximab-Cytarabine for transplant-eligible patients with mantle cell lymphoma.利妥昔单抗-苯达莫司汀和利妥昔单抗-阿糖胞苷用于适合移植的套细胞淋巴瘤患者的2期研究。
Br J Haematol. 2016 Apr;173(1):89-95. doi: 10.1111/bjh.13929. Epub 2016 Jan 5.
10
[CAR-T cell therapy in a patient with relapsed/refractory mantle cell lymphoma].[复发性/难治性套细胞淋巴瘤患者的嵌合抗原受体T细胞疗法]
Recenti Prog Med. 2025 Mar;116(3):e50-e57. doi: 10.1701/4460.44570.

本文引用的文献

1
Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network.伊布替尼联合免疫化疗联合或不联合自体造血干细胞移植与免疫化疗和自体造血干细胞移植治疗未经治疗的套细胞淋巴瘤患者（TRIANGLE）：欧洲套细胞淋巴瘤网络的一项三臂、随机、开放标签、III 期优效性试验。
Lancet. 2024 May 25;403(10441):2293-2306. doi: 10.1016/S0140-6736(24)00184-3. Epub 2024 May 2.
2
Long-Term Follow-Up of Rituximab Maintenance in Young Patients With Mantle-Cell Lymphoma Included in the LYMA Trial: A LYSA Study.LYMA 试验中包含的套细胞淋巴瘤年轻患者利妥昔单抗维持治疗的长期随访：LYSA 研究。
J Clin Oncol. 2024 Mar 1;42(7):769-773. doi: 10.1200/JCO.23.01586. Epub 2023 Dec 18.
3
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.《世界卫生组织造血与淋巴组织肿瘤分类》第五版：淋巴肿瘤。
Leukemia. 2022 Jul;36(7):1720-1748. doi: 10.1038/s41375-022-01620-2. Epub 2022 Jun 22.
4
Hematopoietic cell transplantation for mantle cell lymphoma.造血干细胞移植治疗套细胞淋巴瘤。
Int J Hematol. 2022 Mar;115(3):301-309. doi: 10.1007/s12185-022-03294-z. Epub 2022 Jan 29.
5
Bendamustine-induced rash is associated with a favorable prognosis in patients with indolent B-cell lymphoma.苯达莫司汀所致皮疹与惰性 B 细胞淋巴瘤患者的良好预后相关。
J Clin Exp Hematop. 2022 Mar 9;62(1):18-24. doi: 10.3960/jslrt.21018. Epub 2021 Dec 28.
6
Bendamustine and rituximab as induction therapy in both transplant-eligible and -ineligible patients with mantle cell lymphoma.苯达莫司汀和利妥昔单抗作为诱导治疗用于适合和不适合移植的套细胞淋巴瘤患者。
Blood Adv. 2020 Aug 11;4(15):3486-3494. doi: 10.1182/bloodadvances.2020002068.
7
R-High-CHOP/CHASER/LEED with autologous stem cell transplantation in newly diagnosed mantle cell lymphoma: JCOG0406 STUDY.在新诊断的套细胞淋巴瘤中采用 R-High-CHOP/CHASER/LEED 联合自体干细胞移植：JCOG0406 研究。
Cancer Sci. 2018 Sep;109(9):2830-2840. doi: 10.1111/cas.13719. Epub 2018 Jul 28.
8
Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety.在 GALLIUM 研究中，奥滨尤妥珠单抗或利妥昔单抗联合化疗治疗初治滤泡性淋巴瘤：化疗对疗效和安全性的影响。
J Clin Oncol. 2018 Aug 10;36(23):2395-2404. doi: 10.1200/JCO.2017.76.8960. Epub 2018 Jun 1.
9
Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma.套细胞淋巴瘤自体干细胞移植后利妥昔单抗的应用。
N Engl J Med. 2017 Sep 28;377(13):1250-1260. doi: 10.1056/NEJMoa1701769.
10
Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network.在年龄为 65 岁或以下的套细胞淋巴瘤（MCL Younger）患者中，在自体干细胞移植前给予高剂量阿糖胞苷联合免疫化疗：欧洲套细胞淋巴瘤网络的一项随机、开放标签、3 期试验。
Lancet. 2016 Aug 6;388(10044):565-75. doi: 10.1016/S0140-6736(16)00739-X. Epub 2016 Jun 14.